Carregando…
XENE
Xenon Pharmaceuticals Inc.
NASDAQ· Healthcare· Biotechnology
$59.99-3.13%
Indicadores
- Market cap
- $5.81B
- P/L
- —
- P/L projetado
- —
- P/VP
- 4.7x
- Dividend yield
- —
- EPS
- -$4.74
- ROE
- -43.62%
- Margem líquida
- 0.00%
- Crescimento de receita
- —
- Beta
- 0.63
- Máxima 52 semanas
- $72.66
- Mínima 52 semanas
- $35.60
Histórico
Como a empresa evoluiu, ano a ano. Receita e dívida vêm dos demonstrativos anuais; os dividendos, dos próprios pagamentos, que alcançam mais anos.
As barras são um saldo na data de fechamento; as linhas são o que aconteceu ao longo do ano. Receita acima do patrimônio é o normal, não anomalia — significa que a empresa gira o capital mais de uma vez por ano.
Investidores posicionados
Grandes gestores que reportaram esta ação no 13F mais recente.
Sobre a empresa
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
- 358
- Burnaby, Canada
Descrição da empresa fornecida pelo Yahoo Finance. A descrição é publicada pela fonte apenas em inglês.